|
ZNF330 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.88737914186277E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.30926389122033E-14 |
| Normal-vs-Stage2 |
1.03870023693275E-10 |
| Normal-vs-Stage3 |
1.63080660087189E-12 |
| Normal-vs-Stage4 |
2.22044604925031E-16 |
| Stage1-vs-Stage2 |
5.295900E-02 |
| Stage1-vs-Stage3 |
4.260400E-01 |
| Stage1-vs-Stage4 |
1.830290E-02 |
| Stage2-vs-Stage3 |
2.233700E-02 |
| Stage2-vs-Stage4 |
1.439550E-03 |
| Stage3-vs-Stage4 |
1.521820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06581410364015E-14 |
| Normal-vs-AfricanAmerican |
8.97837360014364E-13 |
| Normal-vs-Asian |
1.27675647831893E-14 |
| Caucasian-vs-AfricanAmerican |
9.836200E-01 |
| Caucasian-vs-Asian |
8.106000E-01 |
| AfricanAmerican-vs-Asian |
8.549400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.25455201782643E-14 |
| Normal-vs-Female |
1.64690483472896E-12 |
| Male-vs-Female |
7.155600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63336011382853E-12 |
| Normal-vs-Age(41-60Yrs) |
2.37587727269783E-14 |
| Normal-vs-Age(61-80Yrs) |
1.66500147003035E-12 |
| Normal-vs-Age(81-100Yrs) |
4.968800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.282800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.313000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.958800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.151800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.868600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.305400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.819550E-01 |
| Classical-VS-Follicular |
3.419600E-04 |
| Classical-VS-Other |
5.360800E-01 |
| Classical-VS-Normal |
1.47659662275146E-14 |
| Tall-VS-Follicular |
1.648190E-04 |
| Tall-VS-Other |
9.470400E-01 |
| Tall-VS-Normal |
1.55431223447522E-15 |
| Follicular-VS-Other |
1.069610E-01 |
| Follicular-VS-Normal |
5.17379472597668E-11 |
| Other-VS-Normal |
4.64239999997673E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02473585172902E-13 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
6.647600E-04 |
|
|
